Pfizer (PFE) Consolidated Net Income (2009 - 2026)

Pfizer has disclosed Consolidated Net Income across 18 years of filings, most recently posting -$13.0 million for Q1 2026.

• In Q1 2026, Consolidated Net Income changed N/A year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 33.33% YoY), while the FY2025 annual figure was $25.0 million, up 127.27% from the prior year.
• Consolidated Net Income eased to -$13.0 million in Q1 2026, from $25.0 million in the prior quarter.
• Over the last five years, Consolidated Net Income for PFE reached as high as $34.0 million in Q3 2022 and fell as low as -$26.0 million in Q4 2023.
• The 5-year median for Consolidated Net Income is -$3.5 million (2023), against an average of $416666.7.
• Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 1000.0% — and 2024, when it soared 950.0%.
• A 5-year view of Consolidated Net Income shows it stood at -$21.0 million in 2022, then slipped by 23.81% to -$26.0 million in 2023, then soared by 69.23% to -$8.0 million in 2024, then jumped by 412.5% to $25.0 million in 2025, then tumbled by 152.0% to -$13.0 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$13.0 million, $25.0 million, and -$8.0 million for Q1 2026, Q2 2025, and Q3 2024 respectively.